Real-world analysis of the safety/tolerability of gilteritinib in combination with mold-active azole prophylaxis.

Autor: King AC; Department of Pharmacy, Clinical Programs, Memorial Sloan Kettering Cancer, New York, NY, USA., Derkach A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Weis TM; Department of Pharmacy, Clinical Programs, Memorial Sloan Kettering Cancer, New York, NY, USA., Stump SE; Department of Pharmacy, Clinical Programs, Vanderbilt University Medical Center, Nashville, TN, USA., Ciervo JR; Department of Pharmacy, Clinical Programs, Memorial Sloan Kettering Cancer, New York, NY, USA., Ranaghan CP; Department of Nursing, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Stein ES; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: steine@mskcc.org.
Jazyk: angličtina
Zdroj: Leukemia research [Leuk Res] 2022 Nov; Vol. 122, pp. 106929. Date of Electronic Publication: 2022 Sep 06.
DOI: 10.1016/j.leukres.2022.106929
Abstrakt: Competing Interests: Declaration of Competing Interest A.C.K. has received advisory/consulting fees from: Astellas and Blueprint Medicines. E.M.S. has received advisory/consulting fees from: Foghorn Therapeutics; Blueprint Medicines; Gilead Sciences; Abbvie; Janssen Pharmaceuticals; Genentech; Jazz Pharmaceuticals; Bristol Myers Squibb; Celgene; Daiichi Sankyo; Astellas; Novartis; Agios Pharmaceuticals; Syros Pharmaceuticals, Inc; Syndax Pharmaceuticals. Remaining authors have nothing to disclose.
Databáze: MEDLINE
Externí odkaz: